# US 12,180,290 B2 · Antibodies to canine and feline oncostatin M receptor beta and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,290 B2
- Document ID: US12180290B2
- Status: Granted
- Kind: B2
- Application number: 17/503,592
- Filed: 2021-10-18
- Published: 2022-06-09
- Granted: 2024-12-31
- Earliest claimed: 2020-10-19
- Assignees: Zoetis Services LLC
- Applicants: Zoetis Services LLC
- Inventors: Gary Francis Bammert; Andrea Joy Gonzales
- Web page: https://patentgrep.com/patent/US12180290B2

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 17/00: Drugs for dermatological disorders
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/715: for cytokines; for lymphokines; for interferons
- G01N 2333/7155: for interleukins [IL]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides an isolated antibody, or antigen-binding portion thereof that specifically binds to canine or feline Oncostatin M receptor Beta (OSMR-β) or both, wherein the antibody antagonizes IL-31-mediated signaling or OSM-mediated signaling or both in a canine and/or feline cell.

## Claims

### Claim 1

An isolated antibody, or antigen-binding portion thereof that specifically binds to canine or feline Oncostatin M receptor Beta (OSMR-β) or both, comprising a combination of complementary determining region (CDR) sequences selected from the group consisting of:
1) 02D09: variable heavy (VH)-CDR1 of SEQ ID NO: 1
(DYGMH),
VH-CDR2 of SEQ ID NO: 2 (YISSGSRAVFFADTVKG),
VH-CDR3 of SEQ ID NO: 3 (DRYDGRGFAY),
variable light (VL)-CDR1 of SEQ ID NO: 4
(RASQSISNNLH),
VL-CDR2 of SEQ NO: 5 (YASQSIS), and
VL-CDR3 of SEQ ID NO: 6 (QQSNSWPLT);
2) 09E09: VH-CDR1 of SEQ ID NO: 7 (SYAMS),
VH-CDR2 of SEQ ID NO: 8 (YISSGGDYIYYADTVKG),
VH-CDR3 of SEQ ID NO: 9 (DPITGTFAY),
VL-CDR1 of SEQ ID NO: 10 (RASQDINNYLN),
VL-CDR2 of SEQ ID NO: 11 (YTSTLHS), and
VL-CDR3 of SEQ ID NO: 12 (QQGNTLPWT);
3) 10F07: VH-CDR1 of SEQ ID NO: 13 (SYAMS),
VH-CDR2 of SEQ ID NO: 14 (YISSGGDYFYYADTVKG),
VH-CDR3 of SEQ ID NO: 15 (DPITGTFAY),
VL-CDR1 of SEQ ID NO: 16 (RASQDITNYLN),
VL-CDR2 of SEQ ID NO: 17 (YTSTLHS), and
VL-CDR3 of SEQ ID NO: 18 (QQGHMLPWT);
4) 14C04: VH-CDR1 of SEQ ID NO: 19 (NYWMN),
VH-CDR2 of SEQ ID NO: 20 (QIYPGHVNTNYNGNFKD),
VH-CDR3 of SEQ ID NO: 21 (SADNSGFVLFAY),
VL-CDR1 of SEQ ID NO: 22 (RASKSVSTSGYSYLH),
VL-CDR2 of SEQ ID NO: 23 (LASNLES), and
VL-CDR3 of SEQ ID NO: 24 (QHSRELPLT);
5) 19F07: VH-CDR1 of SEQ ID NO: 25 (DYYMA),
VH-CDR2 of SEQ ID NO: 26 (NINYDGSSTYYLDSLKS),
VH-CDR3 of SEQ ID NO: 27 (GLTWDFDV),
VL-CDR1 of SEQ ID NO: 28 (KASQDVDTAVA),
VL-CDR2 of SEQ ID NO: 29 (LASTRHT), and
VL-CDR3 of SEQ ID NO: 30 (QQYSRFPLT);
or
6) CDR variants of 1, 2, 3, 4, or 5.

### Claim 2 (depends on 1)

The antibody, or antigen-binding portion thereof of claim 1, wherein the antibody antagonizes IL-31-mediated signaling or OSM-mediated signaling or both in a canine and/or feline cell.

### Claim 3 (depends on 2)

The antibody, or antigen-binding portion thereof of claim 2, wherein the antibody antagonizes both IL-31-mediated signaling and OSM-mediated signaling in a canine and/or feline cell.

### Claim 4 (depends on 1)

The antibody of claim 1, comprising at least one of the group consisting of:
(a) a variable heavy chain comprising
(MU_02D09_VH)
SEQ ID NO: 31
EVQLVESGGGLVKPGGSLTLSCAASGFTFSDYGMHWLRQAPEKGLEWVAYISSGSRAVFFAD
TVKGRFTISRDNAKNTLFLQMTSLRSDDTAMYYCARDRYDGRGFAYWGQGTLVTVSA,
(MU_09E09_VH)
SEQ ID NO: 35
DVKLVESGEGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVAYISSGGDYIYYADT
VKGRFTISRDNARNTLYLQMSSLKSEDTAMYYCTRDPITGTFAYWGQGTLVTVSA,
(MU_10F07_VH)
SEQ ID NO: 39
DVKLVESGEGLVKPGGSLKLSCAASGFTFSSYAMSWVRQTPEKRLEWVTYISSGGDYFYYAD
TVKGRFTISRDNARNTLYLQMSSLKSEDTAMYYCTRDPITGTFAYWGQGTLVTVSA,
(MU_14C04_VH)
SEQ ID NO: 43
EVQLQESGAELVKPGASVKISCKASGYAFSNYWMNWMKQRPGKGLEWIGQIYPGHVNTNYN
GNFKDKATLTADKSSSTAYMQLSSLTSEDSAVYFCARSADNSGFVLFAYWGQGTLVTVS,
(MU_19F07_VH)
SEQ ID NO: 47
EVKLVESEGGLVQPGSSMKLSCTASGFTFSDYYMAWVRQVPEKGLEWVANINYDGSSTYYLD
SLKSRFIISRDNAKNILYLQMSSLKSEDTATYYCARGLTWDFDVWGTGTTVTVSS,
(FEL_02D09_VH1)
SEQ ID NO: 51
DVQLVESGGDLVKPGGSLRLTCVASGFTYSDYGMHWVRQAPGKGLQWVAYISSGSRAVFFA
DTVKGRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRDRYDGRGFAYWGQGTLVTVSS,
(FEL_02D09_VH2)
SEQ ID NO: 53
DVQLVESGGDLVKPGGSLRLTCVASGFTFSDYGMHWVRQAPGKGLQWVAYISSGSRAVFFA
DTVKGRFTISRDNAKNTLYLQMNGLRTEDTATYYCARDRYDGRGFAYWGQGTLVTVSS,
(CAN_09E09_VH1)
SEQ ID NO: 59
EVQLVESGGDLVKPGGSLRLSCVASGFTFSSYAMSWVRQAPGKGLQWVAYISSGGDYIYYAD
TVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRDPITGTFAYWGQGTLVTVSS,
(CAN_09E09_VH2)
SEQ ID NO: 61
EVQLVESGGDLVKPAGSLTLSCLASGFTFSSYAMSWVRQTPEKGLQWVAYISSGGDYIYYADT
VKGRFTISRDNAKNTLYLQMNSLRDEDTAVYYCARDPITGTFAYWGQGTLVTVSS,
(FEL_09E09_VH1)
SEQ ID NO: 67
DVQLVESGGDLVKPGGSLRLTCVASGFTYSSYAMSWVRQAPGKGLQWVAYISSGGDYIYYAD
TVKGRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRDPITGTFAYWGQGTLVTVSS,
(FEL_09E09_VH2)
SEQ ID NO: 69
DVQLVESGGNLVKPGGSLRLTCVASGFTFSSYAMSWVRQAPGKGLQWVAYISSGGDYIYYAD
TVKGRFTISKDNAKNTLYLQMNSLKTEDTATYYCARDPITGTFAYWGQGTLVTVSS,
(CAN_10F07_VH1)
SEQ ID NO: 75
EVQLVESGGDLVKPGGSLRLSCVASGFTFSSYAMSWVRQAPGKGLQWVAYISSGGDYFYYA
DTVKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRDPITGTFAYWGQGTLVTVSS,
(CAN_10F07_VH2)
SEQ ID NO: 79
EVQLVESGGDLVKPAGSLTLSCLASGFTFSSYAMSWVRQTPEKGLQWVAYISSGGDYFYYAD
TVKGRFTISRDNAKNTLYLQMNSLRDEDTAVYYCARDPITGTFAYWGQGTLVTVSS,
(FEL_10F07_VH1)
SEQ ID NO: 83
DVQLVESGGDLVKPGGSLRLTCVASGFTYSSYAMSWVRQAPGKGLQWVAYISSGGDYFYYA
DTVKGRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRDPITGTFAYWGQGTLVTVSS,
(FEL_10F07_VH2)
SEQ ID NO: 87
DVQLVESGGDLVKPGGSLRLTCVASGFTFSSYAMSWVRQAPGKGLQWVAYISSGGDYFYYA
DTVKGRFTISRDDAKNTLYLQMSSLKTEDTATYYCTGDPITGTFAYWGQGTLVTVSS,
(CAN_19F07_VH1)
SEQ ID NO: 91
EVQLVESGGDLVKPGGSLRLSCVASGFTFSDYYMAWVRQAPGKGLQWVANINYDGSSTYYLD
SLKSRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGLTWDFDVWGQGTLVTVSS,
(CAN_19F07_VH2)
SEQ ID NO: 95
EVQLVESGGDLVKPAGSLTLSCLASGFTFSDYYMAWVRQTPEKGLQWVANINYDGSSTYYLD
SLKSRFTISRDNAKNTLYLQMNSLRDEDTAVYYCARGLTWDFDVWGQGTLVTVSS,
(FEL_19F07_VH1)
SEQ ID NO: 99
DVQLVESGGDLVKPGGSLRLTCVASGFTYSDYYMAWVRQAPGKGLQWVANINYDGSSTYYL
DSLKSRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRGLTWDFDVWGQGTLVTVSS,
(FEL_19F07_VH2)
SEQ ID NO: 103
DVQLVESGGNLVKPGGSLRLTCVASGFTFSDYYMAWVRQAPGKGLQWVANINYDGSSTYYLD
SLKSRFTISRDNAKNTLYLQMNSLKTEDTATYYCARGLTWDFDVWGQGTLVTVSS,
(CAN_14C04_VH1)
SEQ ID NO: 127
EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYWMNWVRQAPGKGLQWVAQIYPGHVNTNYN
GNFKDRFTISRDNARNTVYLQMNSLRAEDTAVYYCARSADNSGFVLFAYWGQGTLVTVSS,
or
(CAN_14C04_VH2)
SEQ ID NO: 129
EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYWMNWVRQSPGKGLQWVAQIYPGHVNTNYN
GNFKDRFTISRDNAKNTLYLQMNSLRAEDTAVYFCARSADNSGFVLFAYWGQGTLVTVSS;
and
(b) a variable light chain comprising
(MU_02D09_VL)
SEQ ID NO: 33
DIVLTQSPATLSVTPGDSVSLSCRASQSISNNLHWYQQTSHESPRLLITYASQSISGIPSRFSGS
GSGTDFTLSINSVETEDFGMYFCQQSNSWPLTFGAGTKLELK,
(MU_09E09_VL)
SEQ ID NO: 37
DLQMTQTTSSLSASLGDRVTISCRASQDINNYLNWYQQKPDGTVKLLIYYTSTLHSGVPSRFSG
SGSGTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK,
(MU_10F07_VL)
SEQ ID NO: 41
DIQMTQTTSSLSASLGDRVTISCRASQDITNYLNWYQQKPDGTVKLLIYYTSTLHSGVPSRFSG
SGSGTDFSLTISNLEQEDIATYFCQQGHMLPWTFGGGTKLEIK,
(MU_14C04_VL)
SEQ ID NO: 45
DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSYLHWYQQKPGQPPKLLIFLASNLESGVPA
RFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPLTFGAGTKLELK,
(MU_19F07_VL)
SEQ ID NO: 49
DIVMTQSHKFMSPSVGDRVSITCKASQDVDTAVAWYQQKPGQSPKWYLASTRHTGVPDRFT
GSGSGTDFTLTISNVQSEDLADYFCQQYSRFPLTFGAGTKLELK,
(FEL_02D09_VL1)
SEQ ID NO: 55
EIQMTQSPSSLSASPGDRVTITCRASQSISNNLHWYQQKPGKVPKLLIYYASQSISGVPSRFSG
SGSGTDFTLTISSLEPEDAATYYCQQSNSWPLTFGQGT,
(FEL_02D09_VL2)
SEQ ID NO: 57
DIVMTQTPLSLSVTPGESASISCRASQSISNNLHWYLQKSGQSPRRLIYYASQSISGVPDRFSG
SGSGTDFTLRISRVEADDVGVYYCQQSNSWPLTFGQGT,
(CAN_09E09_VL1)
SEQ ID NO: 63
EIVMTQSPASLSLSQEEKVTITCRASQDINNYLNWYQQKPGQAPKLLIYYTSTLHSGVPSRFSG
SGSGTDFSFTISSLEPEDVAVYYCQQGNTLPWTFGQGT,
(CAN_09E09_VL2)
SEQ ID NO: 65
DIVLTQPTSVSGSLGQRVTISCRASQDINNYLNWYQQLPGKAPKLLVYYTSTLHSGVPDRFSGS
NSGSSATLTITGLQAEDEADYYCQQGNTLPWTFGQGT,
(FEL_09E09_VL1)
SEQ ID NO: 71
EIQMTQSPSSLSASPGDRVTITCRASQDINNYLNWYQQKPGKVPKLLIYYTSTLHSGVPSRFSG
SGSGTDFTLTISSLEPEDAATYYCQQGNTLPWTFGQGT,
(FEL_09E09_VL2)
SEQ ID NO: 73
DITMTQSPGSLAGSPGQQVTMNCRASQDINNYLNWYQQKPGQHPKLLIYYTSTLHSGVPDRF
SGSGSGTDFTLTISNLQAEDVASYYCQQGNTLPWTFGQGT,
(CAN_10F07_VL1)
SEQ ID NO: 77
EIVMTQSPASLSLSQEEKVTITCRASQDITNYLNWYQQKPGQAPKLLIYYTSTLHSGVPSRFSG
SGSGTDFSFTISSLEPEDVAVYYCQQGHMLPWTFGQGT,
(CAN_10F07_VL2)
SEQ ID NO: 81
DIVLTQPTSVSGSLGQRVTISCRASQDITNYLNWYQQLPGKAPKLLVYYTSTLHSGVPDRFSGS
NSGSSATLTITGLQAEDEADYYCQQGHMLPWTFGQGT,
(FEL_10F07_VL1)
SEQ ID NO: 85
EIQMTQSPSSLSASPGDRVTITCRASQDITNYLNWYQQKPGKVPKLLIYYTSTLHSGVPSRFSG
SGSGTDFTLTISSLEPEDAATYYCQQGHMLPWTFGQGT,
(FEL_10F07_VL2)
SEQ ID NO: 89
DITMTQSPGSLAGSPGQQVTMNCRASQDITNYLNWYQQKPGQHPKLLIYYTSTLHSGVPDRFS
GSGSGTDFTLTISNLQAEDVASYYCQQGHMLPWTFGQGT,
(CAN_19F07_VL1)
SEQ ID NO: 93
EIVMTQSPASLSLSQEEKVTITCKASQDVDTAVAWYQQKPGQAPKWYLASTRHTGVPSRFSG
SGSGTDFSFTISSLEPEDVAVYYCQQYSRFPLTFGQGT,
(CAN_19F07_VL2)
SEQ ID NO: 97
DIVMTQTPLSLSVSPGETASISCKASQDVDTAVAWFRQKPGQSPQRLIYLASTRHTGVPDRFS
GSGSGTDFTLRISRVEADDTGVYYCQQYSRFPLTFGQGT,
(FEL_19F07_VL1)
SEQ ID NO: 101
EIQMTQSPSSLSASPGDRVTITCKASQDVDTAVAWYQQKPGKVPKLLIYLASTRHTGVPSRFS
GSGSGTDFTLTISSLEPEDAATYYCQQYSRFPLTFGQGT,
(FEL_19F07_VL2)
SEQ ID NO: 105
DITMTQSPGSLAGSPGQQVTMNCKASQDVDTAVAWYQQKPGQHPKWYLASTRHTGVPDRF
SGSGSGTDFTLTISNLQAEDVASYYCQQYSRFPLTFGQGT,
(CAN_14C04_VL1)
SEQ ID NO: 131
EIVMTQSPASLSLSQEEKVTITCRASKSVSTSGYSYLHWYQQKPGQAPKLLIYLASNLESGVPS
RFSGSGSGTDFSFTISSLEPEDVAVYYCQHSRELPLTFGQGT,
or
(CAN_14C04_VL2)
SEQ ID NO: 133
DIVMTQTPLSLSVSPGETASISCRASKSVSTSGYSYLHWYLQKPGQSPQLLIYLASNLESGVSK
RFSGSGSGTDFTLRISRVEADDTGIYYCQHSRELPLTFGQGT.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein the antibody is chimeric.

### Claim 6 (depends on 1)

The antibody of claim 1, wherein the antibody is caninized or felinized.

### Claim 7 (depends on 1)

The antibody of claim 1, wherein the antibody inhibits or neutralizes an IL-31-mediated or OSM-mediated pruritic or allergic condition in a dog or cat, wherein the IL-31-mediated or OSM-mediated pruritic or allergic condition is selected from the group consisting of atopic dermatitis, allergic dermatitis, and pruritis.

### Claim 8 (depends on 7)

The antibody of claim 7, wherein the IL-31-mediated or OSM-mediated pruritic condition is selected from the group consisting of atopic dermatitis and pruritis.

### Claim 9 (depends on 1)

A veterinary composition comprising a therapeutically effective amount of the antibody of claim 1.